R&D | January 14, 2026
Codexis teams up with Axolabs to advance enzymatic RNA manufacturing
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
Subscribe To Our Newsletter & Stay Updated
